Search Results
Jul 27, 2026, 10:31 ET Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
evolving treatment paradigm.Aquestive Therapeutics' Epinephrine Sublingual Film (ANAPHYLM)Phase IIIANAPHYLM (AQST-109) is an investigational polymer matrix-based epinephrine prodrug being developed by Aquestive Therapeutics for the treatment of severe allergic
More news about: DelveInsight Business Research, LLP
May 03, 2026, 18:30 ET AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: The Rosen Law Firm, P.A.
Apr 30, 2026, 21:30 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
-- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 30, 2026, 09:44 ET AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 30, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt
30, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Aquestive Therapeutics, Inc. (NASDAQ: AQST) to contact the firm. Those who purchased AQST securities between June 16, 2025 and January 8, 2026 may be entitled to recover damages.
More news about: SueWallSt.com
Apr 29, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
April 29, 2026 /PRNewswire/ -- Institutional investors holding positions in Aquestive Therapeutics, Inc. (NASDAQ: AQST) during the period from June 16, 2025 through January 8, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action.
More news about: Levi & Korsinsky
Apr 28, 2026, 09:00 ET AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit - Contact The Gross Law Firm
April 28, 2026 /PRNewswire/ - The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).
More news about: The Gross Law Firm
Apr 27, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.
More news about: Bronstein, Gewirtz & Grossman, LLC
Apr 27, 2026, 06:30 ET AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Apr 23, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt
Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 23, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history
More news about: SueWallSt.com
Apr 22, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky
April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual defendant in a pending securities class
More news about: Levi & Korsinsky, LLP
Apr 22, 2026, 08:26 ET AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 22, 2026, 01:37 ET AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Apr 21, 2026, 09:00 ET AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).
More news about: The Gross Law Firm
Apr 16, 2026, 18:05 ET AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-aquestive-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--aqst-302744210.htmlSOURCE
More news about: Pomerantz LLP
Apr 16, 2026, 09:24 ET AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 16, 2026, 09:00 ET AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
/PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through January 8, 2026. Shareholders who lost money on AQST stock may
More news about: SueWallSt.com
Apr 15, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 15, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history
More news about: Levi & Korsinsky, LLP
Apr 14, 2026, 09:00 ET AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).
More news about: The Gross Law Firm
Apr 11, 2026, 19:27 ET AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Apr 10, 2026, 09:34 ET AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
-- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
Apr 07, 2026, 09:00 ET AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).
More news about: The Gross Law Firm
Apr 07, 2026, 03:38 ET AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.